-
EP2373309
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2373309
| EP2373309 - ANTICANCER COMBINATION COMPRISING DOCETAXEL AND AN ANTISENSE OLIGONUCLEOTIDE [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 15.08.2014 Database last updated on 13.11.2024 | Most recent event Tooltip | 15.08.2014 | Withdrawal of application | published on 17.09.2014 [2014/38] | Applicant(s) | For all designated states Isis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad, CA 92010 / US | [2011/41] | Inventor(s) | 01 /
GRAFF, Jeremy, Richard Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US | [2011/41] | Representative(s) | Hallybone, Huw George Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [N/P] |
| Former [2011/41] | Hallybone, Huw George Carpmaels & Ransford One Southampton Row London WC1B 5HA / GB | Application number, filing date | 09760052.2 | 17.11.2009 | WO2009US64694 | Priority number, date | US20080116861P | 21.11.2008 Original published format: US 116861 P | [2011/41] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2010059589 | Date: | 27.05.2010 | Language: | EN | [2010/21] | Type: | A1 Application with search report | No.: | EP2373309 | Date: | 12.10.2011 | Language: | EN | The application published by WIPO in one of the EPO official languages on 27.05.2010 takes the place of the publication of the European patent application. | [2011/41] | Search report(s) | International search report - published on: | EP | 27.05.2010 | Classification | IPC: | A61K31/337, A61K31/7115, A61K31/712, A61K31/7125, A61K45/06, A61P35/00 | [2011/41] | CPC: |
A61K45/06 (EP,US);
A61K31/337 (EP,US);
A61K31/7115 (EP,US);
A61K31/712 (EP,US);
A61K31/7125 (EP,US);
A61P35/00 (EP);
A61P43/00 (EP)
(-)
| C-Set: |
A61K31/337, A61K2300/00 (EP,US);
A61K31/7115, A61K2300/00 (US,EP);
A61K31/7125, A61K2300/00 (US,EP);
A61K31/712, A61K2300/00 (US,EP) | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR | Title | German: | KOMBINATION GEGEN KREBS AUS DOCETAXEL UND EINEM ANTISENSE-OLIGONUKLEOTID | [2011/41] | English: | ANTICANCER COMBINATION COMPRISING DOCETAXEL AND AN ANTISENSE OLIGONUCLEOTIDE | [2011/41] | French: | ASSOCIATION ANTICANCER CONTENANT DU DOCÉTAXEL ET UN OLIGONUCLÉOTIDE ANTISENS | [2011/41] | Entry into regional phase | 09.06.2011 | National basic fee paid | 09.06.2011 | Designation fee(s) paid | 09.06.2011 | Examination fee paid | Examination procedure | 09.06.2011 | Examination requested [2011/41] | 07.03.2012 | Amendment by applicant (claims and/or description) | 08.05.2014 | Application withdrawn by applicant [2014/38] | Fees paid | Renewal fee | 07.11.2011 | Renewal fee patent year 03 | 07.11.2012 | Renewal fee patent year 04 | 26.12.2013 | Renewal fee patent year 05 | Penalty fee | Additional fee for renewal fee | 30.11.2013 | 05 M06 Fee paid on 26.12.2013 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [ID]WO2005028628 (ISIS PHARMACEUTICALS INC [US], et al) [ID] 1,4,9-10,13-18 * pages 47-48; example -; claim - *; | [A] - MARRA M ET AL, "Anticancer drugs and hyperthermia enhance cytotoxicity induced by polyamine enzymatic oxidation products", AMINO ACIDS ; THE FORUM FOR AMINO ACID AND PROTEIN RESEARCH, SPRINGER-VERLAG, VI, (20070704), vol. 33, no. 2, ISSN 1438-2199, pages 273 - 281, XP019544770 [A] 1-18 * pages 273-279 * DOI: http://dx.doi.org/10.1007/s00726-007-0536-x | [AD] - GRAFF J R ET AL, "Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without tox", THE JOURNAL OF CLINICAL INVESTIGATION SEP 2007, (200709), vol. 117, no. 9, ISSN 0021-9738, pages 2638 - 2648, XP002572954 [AD] 1-18 * page 2645 * DOI: http://dx.doi.org/10.1172/JCI32044 | [A] - SUSAN CLEATOR ET AL, "Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, (20060201), vol. 95, no. 3, ISSN 1573-7217, pages 229 - 233, XP019274969 [A] 1-18 * page 230, column l, paragraph 1 * * page 231, column r, paragraph 4 - page 232 * * page 231, column l, paragraph 3 * |